6BU0 Stock Overview
Primarily develops and sells cancer therapy selection tests in the People's Republic of China. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Burning Rock Biotech Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.41 |
| 52 Week High | US$8.70 |
| 52 Week Low | US$1.41 |
| Beta | 0.14 |
| 11 Month Change | 0% |
| 3 Month Change | -35.32% |
| 1 Year Change | -82.15% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -94.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6BU0 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.8% | -1.3% |
| 1Y | -82.2% | -17.5% | 7.4% |
Return vs Industry: 6BU0 underperformed the German Biotechs industry which returned -17.5% over the past year.
Return vs Market: 6BU0 underperformed the German Market which returned 7.4% over the past year.
Price Volatility
| 6BU0 volatility | |
|---|---|
| 6BU0 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 6.4% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.8% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 6BU0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine 6BU0's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 786 | Yusheng Han | www.brbiotech.com |
Burning Rock Biotech Limited primarily develops and sells cancer therapy selection tests in the People's Republic of China. It operates through three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company primarily offers next-generation sequencing-based tissue and liquid biopsy cancer therapy selection and prognosis prediction tests for various range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.
Burning Rock Biotech Limited Fundamentals Summary
| 6BU0 fundamental statistics | |
|---|---|
| Market cap | €53.00m |
| Earnings (TTM) | -€75.09m |
| Revenue (TTM) | €67.54m |
0.8x
P/S Ratio-0.7x
P/E RatioIs 6BU0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6BU0 income statement (TTM) | |
|---|---|
| Revenue | CN¥509.81m |
| Cost of Revenue | CN¥164.64m |
| Gross Profit | CN¥345.17m |
| Other Expenses | CN¥911.95m |
| Earnings | -CN¥566.78m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -55.25 |
| Gross Margin | 67.71% |
| Net Profit Margin | -111.18% |
| Debt/Equity Ratio | 0% |
How did 6BU0 perform over the long term?
See historical performance and comparison